Physician profile
Walter E Johnston
NPI 1952332181
$1,432.04
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $315 · 2021: $346 · 2022: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $571.54 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $351.91 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $201.67 | 2019-2022 | |
| Glaxosmithkline, LLC. | $67.28 | 2021-2022 | |
| Lilly USA, LLC | $43.22 | 2020-2022 | |
| Abbott Laboratories | $35.08 | 2021 | |
| Abbvie INC. | $28.84 | 2022 | |
| Arbor Pharmaceuticals, INC. | $25.39 | 2019 | |
| Dexcom, INC. | $24.59 | 2021 | |
| Pfizer INC. | $23.17 | 2019-2022 | |
| Mylan Specialty L.P. | $20.67 | 2020 | |
| Amgen INC. | $20.66 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.